Abstract
Microbubble ultrasound contrast agents (UCAs) were recently approved by the Food and Drug administration for non-cardiac imaging. The physical principles of UCAs, methods of administration, dosage, adverse effects, and imaging techniques both current and future are described. UCAs consist of microbubbles in suspension which strongly interact with the ultrasound beam and are readily detectable by ultrasound imaging systems. They are confined to the blood pool when administered intravenously, unlike iodinated and gadolinium contrast agents. UCAs have a proven safety record based on over two decades of use, during which they have been used in echocardiography in the U.S. and for non-cardiac imaging in the rest of the world. Adverse effects are less common with UCAs than CT/MR contrast agents. Compared to CT and MR, contrast-enhanced ultrasound has the advantages of real-time imaging, portability, and reduced susceptibility to metal and motion artifact. UCAs are not nephrotoxic and can be used in renal failure. High acoustic amplitudes can cause microbubbles to fragment in a manner that can result in short-term increases in capillary permeability or capillary rupture. These bioeffects can be beneficial and have been used to enhance drug delivery under appropriate conditions. Imaging with a mechanical index of < 0.4 preserves the microbubbles and is not typically associated with substantial bioeffects. Molecularly targeted ultrasound contrast agents are created by conjugating the microbubble shell with a peptide, antibody, or other ligand designed to target an endothelial biomarker associated with tumor angiogenesis or inflammation. These microbubbles then accumulate in the microvasculature at target sites where they can be imaged. Ultrasound contrast agents are a valuable addition to the diagnostic imaging toolkit. They will facilitate cross-sectional abdominal imaging in situations where contrast-enhanced CT and MR are contraindicated or impractical.
Similar content being viewed by others
References
Huang SF, Chang RF, Moon WK, et al. (2008) Analysis of tumor vascularity using three-dimensional power Doppler ultrasound images. IEEE Trans Med Imaging 27(3):320–330
McDonald DM, Choyke PL (2003) Imaging of angiogenesis: from microscope to clinic. Nat Med 9(6):713–725
Lassau N, Lamuraglia M, Vanel D, et al. (2005) Doppler US with perfusion software and contrast medium injection in the early evaluation of isolated limb perfusion of limb sarcomas: prospective study of 49 cases. Ann Oncol 16(7):1054–1060
Lindner JR, Womack L, Barrett EJ, et al. (2008) Limb stress-rest perfusion imaging with contrast ultrasound for the assessment of peripheral arterial disease severity. JACC Cardiovasc Imaging 1(3):343–350
Darge K, Moeller RT, Trusen A, et al. (2005) Diagnosis of vesicoureteric reflux with low-dose contrast-enhanced harmonic ultrasound imaging. Pediatr Radiol 35(1):73–78
Prefumo F, Serafini G, Martinoli C, et al. (2002) The sonographic evaluation of tubal patency with stimulated acoustic emission imaging. Ultrasound Obstet Gynecol 20(4):386–389
Society, I.C.U. CEUS Around the World. 2017 [cited 2017 October]; Available from: http://www.icus-society.org/attachments/article/103/ICUS%20-%20CEUS%20Around%20the%20World.pdf.
Claudon M, Dietrich CF, Choi BI, et al. (2013) Guidelines and good clinical practice recommendations for Contrast Enhanced Ultrasound (CEUS) in the liver-update 2012: a WFUMB-EFSUMB initiative in cooperation with representatives of AFSUMB, AIUM, ASUM. FLAUS and ICUS. Ultrasound Med Biol 39(2):187–210
Piscaglia F, Nolsøe C, Dietrich CF, et al. (2012) The EFSUMB Guidelines and Recommendations on the Clinical Practice of Contrast Enhanced Ultrasound (CEUS): update 2011 on non-hepatic applications. Ultraschall Med 33(1):33–59
D’Onofrio M, Romanini L, Serra C, et al. (2016) Contrast enhancement ultrasound application in focal liver lesions characterization: a retrospective study about guidelines application (SOCEUS-CEUS survey). J Ultrasound 19(2):99–106
Dawson P, Cosgrove D, Grainger R (1999) Textbook of contrast media. Oxford: ISIS Medical Media
Burns PN (1996) Harmonic imaging with ultrasound contrast agents. Clin Radiol 51(1):50–55
Forsberg F, Merton DA, Liu J, et al. (1998) Clinical applications of ultrasound contrast agents. Ultrasonics 36(1–5):695–701
Schrope BA, Newhouse VL (1993) Second harmonic ultrasonic blood perfusion measurement. Ultrasound Med Biol 19(7):567–579
Bouakaz A, Frigstad S, Ten Cate FJ, et al. (2002) Super harmonic imaging: a new imaging technique for improved contrast detection. Ultrasound Med Biol 28(1):59–68
van Neer PL, Danilouchkine MG, Verweij MD, et al. (2011) Comparison of fundamental, second harmonic, and superharmonic imaging: a simulation study. J Acoust Soc Am 130(5):3148–3157
Lindsey BD, Rojas JD, Dayton PA (2015) On the relationship between microbubble fragmentation, deflation and broadband superharmonic signal production. Ultrasound Med Biol 41(6):1711–1725
Chomas J, Dayton P, May D, Ferrara K (2002) Nondestructive subharmonic imaging. IEEE Trans Ultrason Ferroelectr FreqControl 49(7):883–892
Forsberg F, Shi WT, Goldberg BB (2000) Subharmonic imaging of contrast agents. Ultrasonics 38(1–8):93–98
Shankar PM, Krishna PD, Newhouse VL (1998) Advantages of subharmonic over second harmonic backscatter for contrast-to-tissue echo enhancement. Ultrasound Med Biol 24(3):395–399
Abbott JG (1999) Rationale and derivation of MI and TI: a review. Ultrasound Med Biol 25(3):431–441
Chomas JE, Dayton P, Allen J, et al. (2001) Mechanisms of contrast agent destruction. IEEE Trans Ultrason Ferroelectr Freq Control 48(1):232–248
Lo AH, Kripfgans OD, Carson PL, et al. (2006) Spatial control of gas bubbles and their effects on acoustic fields. Ultrasound Med Biol 32(1):95–106
Caskey CF, Kruse DE, Dayton PA, et al. (2006) Microbubble oscillation in tubes with diameters of 12, 25, and 195 μm. Appl Phys Lett 88(3):033902
Thomas DH, Sboros V, Emmer M, et al. (2013) Microbubble oscillations in capillary tubes. IEEE Trans Ultrason Ferroelectr Freq Control 60(1):105–114
Feingold S, Gessner R, Guracar IM, et al. (2010) Quantitative volumetric perfusion mapping of the microvasculature using contrast ultrasound. Invest Radiol 45(10):669–674
Ghanem A, DeMaria AN, Lohmaier S, et al. (2007) Triggered replenishment imaging reduces variability of quantitative myocardial contrast echocardiography and allows assessment of myocardial blood flow reserve. Echocardiography 24(2):149–158
Pollard RE, Sadlowski AR, Bloch SH, et al. (2002) Contrast-assisted destruction-replenishment ultrasound for the assessment of tumor microvasculature in a rat model. Technol Cancer Res Treat 1(6):459–470
Cosgrove D, Eckersley R, Blomley M, et al. (2001) Quantification of blood flow. Eur Radiol 11(8):1338–1344
Wei K, Jayaweera AR, Firoozan S, et al. (1998) Quantification of myocardial blood flow with ultrasound-induced destruction of microbubbles administered as a constant venous infusion. Circulation 97(5):473–483
Jakobsen JA, Oyen R, Thomsen HS, Morcos SK, Members of Contrast Media Safety Committee of European Society of Urogenital Radiolog (2005) Safety of ultrasound contrast agents. Eur Radiol 15(5):941–945
Wei K, Mulvagh SL, Carson L, et al. (2008) The safety of deFinity and Optison for ultrasound image enhancement: a retrospective analysis of 78,383 administered contrast doses. J Am Soc Echocardiogr 21(11):1202–1206
Hynynen K, McDannold N, Sheikov NA, Jolesz FA, Vykhodtseva N (2005) Local and reversible blood-brain barrier disruption by noninvasive focused ultrasound at frequencies suitable for trans-skull sonications. Neuroimage 24(1):12–20
Piscaglia F, Bolondi L (2006) The safety of Sonovue in abdominal applications: retrospective analysis of 23188 investigations. Ultrasound Med Biol 32(9):1369–1375
Kusnetzky LL, Khalid A, Khumri TM, et al. (2008) Acute mortality in hospitalized patients undergoing echocardiography with and without an ultrasound contrast agent: results in 18,671 consecutive studies. J Am Coll Cardiol 51(17):1704–1706
Main ML, Ryan AC, Davis TE, et al. (2008) Acute mortality in hospitalized patients undergoing echocardiography with and without an ultrasound contrast agent (multicenter registry results in 4,300,966 consecutive patients). Am J Cardiol 102(12):1742–1746
Abdelmoneim SS, Bernier M, Scott CG, et al. (2009) Safety of contrast agent use during stress echocardiography: a 4-year experience from a single-center cohort study of 26,774 patients. JACC Cardiovasc Imaging 2(9):1048–1056
Parker JM, Weller MW, Feinsteinz LM, et al. (2013) Safety of ultrasound contrast agents in patients with known or suspected cardiac shunts. Am J Cardiol 112(7):1039–1045
Bracco Diagnostics (2017) Lumason Prescribing information
GE Healthcare (2012) Optison Prescribing information
Haqshenas SR, Ford IJ, Saffari N (2016) Modelling the effect of acoustic waves on nucleation. J Chem Phys 145(2):024315
Marquet F, Teichert T, Wu SY, et al. (2014) Real-time, transcranial monitoring of safe blood-brain barrier opening in non-human primates. PLoS ONE 9(2):e84310
Karshafian R, Bevan PD, Williams R, Samac S, Burns PN (2009) Sonoporation by ultrasound-activated microbubble contrast agents: effect of acoustic exposure parameters on cell membrane permeability and cell viability. Ultrasound Med Biol 35(5):847–860
Ferrara K, Pollard R, Borden M (2007) Ultrasound microbubble contrast agents: fundamentals and application to gene and drug delivery. Annu Rev Biomed Eng 9:415–447
Price RJ, Skyba DM, Kaul S, Skalak TC (1998) Delivery of colloidal, particles and red blood cells to tissue through microvessel ruptures created by targeted microbubble destruction with ultrasound. Circulation 98(13):1264–1267
Miller DL, Quddus J (2000) Diagnostic ultrasound activation of contrast agent gas bodies induces capillary rupture in mice. Proc Natl Acad Sci USA 97(18):10179–10184
Shigeta K, Itoh K, Ookawara S, Taniguchi N, Omoto K (2004) Endothelial cell injury and platelet aggregation induced by contrast ultrasonography in the rat hepatic sinusoid. J Ultrasound Med 23(1):29–36
Burgess A, Hynynen K (2016) Microbubble-assisted ultrasound for drug delivery in the brain and central nervous system. Adv Exp Med Biol 880:293–308
Caskey CF (2017) Ultrasound molecular imaging and drug delivery. Mol Imaging Biol 19(3):336–340
Dimcevski G, Kotopoulis S, Bjånes T, et al. (2016) A human clinical trial using ultrasound and microbubbles to enhance gemcitabine treatment of inoperable pancreatic cancer. J Control Release 243:172–181
Alexandrov AV (2006) Ultrasound enhanced thrombolysis for stroke. Int J Stroke 1(1):26–29
Kutty S, Xie F, Gao S, et al. (2010) Sonothrombolysis of intra-catheter aged venous thrombi using microbubble enhancement and guided three-dimensional ultrasound pulses. J Am Soc Echocardiogr 23(9):1001–1006
Jiang N, Xie B, Zhang X, et al. (2014) Enhancing ablation effects of a microbubble-enhancing contrast agent (“SonoVue”) in the treatment of uterine fibroids with high-intensity focused ultrasound: a randomized controlled trial. Cardiovasc Intervent Radiol 37(5):1321–1328
Kopechek JA, Park EJ, Zhang YZ, et al. (2014) Cavitation-enhanced MR-guided focused ultrasound ablation of rabbit tumors in vivo using phase shift nanoemulsions. Phys Med Biol 59(13):3465–3481
Moyer LC, Timbie KF, Sheeran PS, et al. (2015) High-intensity focused ultrasound ablation enhancement in vivo via phase-shift nanodroplets compared to microbubbles. J Ther Ultrasound 3:7
ter Haar G (2009) Safety and bio-effects of ultrasound contrast agents. Med Biol Eng Comput 47(8):893–900
AIUM (2015) Statement on Mammalian Biological Effects in Tissues with Naturally Occurring Gas Bodies
B.M.S. (2008) Definity package insert
Sontum PC (2008) Physicochemical characteristics of Sonazoid, a new contrast agent for ultrasound imaging. Ultrasound Med Biol 34(5):824–833
Gessner R, Dayton PA (2010) Advances in molecular imaging with ultrasound. Mol Imaging 9(3):117–127
Lindner JR (2004) Molecular imaging with contrast ultrasound and targeted microbubbles. J Nucl Cardiol 11(2):215–221
Smeenge M, Tranquart F, Mannaerts CK, et al. (2017) First-in-human ultrasound molecular imaging with a VEGFR2-specific ultrasound molecular contrast agent (BR55) in prostate cancer: a safety and feasibility pilot study. Invest Radiol 52(7):419–427
Willmann JK, Bonomo L, Testa AC, et al. (2017) Ultrasound molecular imaging with BR55 in patients with breast and ovarian lesions: first-in-human results. J Clin Oncol 35(19):2133–2140
Zhou J, Wang H, Zhang H, et al. (2016) VEGFR2-targeted three-dimensional ultrasound imaging can predict responses to antiangiogenic therapy in preclinical models of colon cancer. Cancer Res 76(14):4081–4089
Streeter JE, Gessner RC, Tsuruta J, et al. (2011) Assessment of molecular imaging of angiogenesis with three-dimensional ultrasonography. Mol Imaging 10(6):7290
Sirsi SR, Flexman ML, Vlachos F, et al. (2012) Contrast ultrasound imaging for identification of early responder tumor models to anti-angiogenic therapy. Ultrasound Med Biol 38(6):1019–1029
Deshpande N, Lutz AM, Ren Y, et al. (2012) Quantification and monitoring of inflammation in murine inflammatory bowel disease with targeted contrast-enhanced US. Radiology 262(1):172–180
Villanueva FS, Lu E, Bowry S, et al. (2007) Myocardial ischemic memory imaging with molecular echocardiography. :Circulation 115(3):345–352
Abou-Elkacem L, Bachawal SV, Willmann JK (2015) Ultrasound molecular imaging: moving toward clinical translation. Eur J Radiol 84(9):1685–1693
Gessner R, Lukacs M, Lee M, et al. (2010) High-resolution, high-contrast ultrasound imaging using a prototype dual-frequency transducer: in vitro and in vivo studies. Trans Ultrason Ferroelectr Freq Control 57(8):1772–1781
Hu X, Zheng H, Kruse DE, et al. (2010) A sensitive TLRH targeted imaging technique for ultrasonic molecular imaging. IEEE Trans Ultrason Ferroelectr Freq Control 57(2):305–316
Shelton SE, Lee YZ, Lee M, et al. (2015) Quantification of microvascular tortuosity during tumor evolution using acoustic angiography. Ultrasound Med Biol 41(7):1896–1904
Shelton SE, Lindsey BD, Dayton PA, Lee YZ (2017) First-in-human study of acoustic angiography in the breast and peripheral vasculature. Ultrasound Med Biol 43(12):2939–2946
Leow CH, Bazigou E, Eckersley RJ, et al. (2015) Flow velocity mapping using contrast enhanced high-frame-rate plane wave ultrasound and image tracking: methods and initial in vitro and in vivo evaluation. Ultrasound Med Biol 41(11):2913–2925
Lin F, Shelton SE, Espíndola D, et al. (2017) 3-D ultrasound localization microscopy for identifying microvascular morphology features of tumor angiogenesis at a resolution beyond the diffraction limit of conventional ultrasound. Theranostics 7(1):196–204
Errico C, Pierre J, Pezet S, et al. (2015) Ultrafast ultrasound localization microscopy for deep super-resolution vascular imaging. Nature 527(7579):499–502
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Disclosures
Paul A. Dayton is an inventor on several patents involving microbubble technology and acoustic angiography, and is a co-founder of SonoVol, Inc. and Triangle Biotechnology, Inc, which have licensed some of these patents. Wui K Chong is on the Lumason advisory board of Bracco Diagnostics.
Ethical approval
This article does not contain any studies with human participants or animals performed by any of the authors.
Rights and permissions
About this article
Cite this article
Chong, W.K., Papadopoulou, V. & Dayton, P.A. Imaging with ultrasound contrast agents: current status and future. Abdom Radiol 43, 762–772 (2018). https://doi.org/10.1007/s00261-018-1516-1
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00261-018-1516-1